Accelerate Diagnostics, Inc. announced financial results for the fourth quarter and full year ended December 31, 2021.
TUCSON, Ariz., March 8, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021.
Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc., commented, “The addition of new contracts, clinically live customers, and new prospects to our sales funnel, made the fourth quarter our most commercially productive quarter of the year. Strong R&D execution in 2021 has enabled the sale and early marketing of our expanded product portfolio. The new PhenoAST Test Kit is being well received in the market, and customer interest for Accelerate Arc is accelerating ahead of our launch later this month. We expect continued improvement in our level of commercial activity on the back of strong interest in these new products and an improved hospital environment in 2022.”
Fourth Quarter 2021 Highlights
- Added 16 contracted instruments in the quarter and brought 13 instruments live in the U.S.
- Additionally, contracted 14 Pheno instruments with distributors and new customers in EMEA in the quarter.
- Ended the fourth quarter with 313 U.S. live revenue-generating instruments, with another 81 U.S. contracted Pheno instruments not yet live.
- Net sales of $3.3 million, compared to $3.1 million in the fourth quarter of 2020, or a 6% increase.
- Gross margin excluding non-cash adjustments to inventory was 35% for the quarter, compared to 37% in the fourth quarter of 2020. This decrease was the result of pandemic-related effects on manufacturing.
- Selling, general, and administrative expenses for the quarter were $11.5 million, compared to $11.2 million in the fourth quarter of 2020. This slight increase was driven by increases to non-cash stock-based compensation expense. Excluding non-cash stock-based compensation expense, SG&A costs decreased due to cost savings initiatives.
- Research and development (R&D) costs for the quarter were $4.6 million, compared to $5.1 million in the fourth quarter of 2020. This decrease was the result of Arc costs decreasing in the period partially offset by increases in Pheno II program investment.
- Net loss was $22.8 million in the fourth quarter, or $0.34 per share, which included $3.0 million in non-cash stock-based compensation expense and $4.5 million from a non-cash inventory write-down. Net loss excluding non-cash charges was $15.3 million in the fourth quarter, or $0.23 per share.
- Net cash used in the quarter was $13.3 million, and the company ended the quarter with total cash, investments, and cash equivalents of $63.6 million.
2021 Full Year Highlights
- Net sales were $11.8 million for the year as compared to $11.2 million from the same period in the prior year, or 5% growth.
- Gross margin excluding non-cash adjustments to inventory valuation was 35% for the year, compared to 40% for the prior year. This decrease was the result of pandemic-related effects on manufacturing.
- Selling, general, and administrative expenses were $49.2 million for the year, compared to $46.9 million in 2020. This increase was driven by increases to non-cash stock-based compensation expense. Excluding this non-cash expense, SG&A decreased year-over-year due to cost savings initiatives.
- Research and development (R&D) costs were $21.9 million year-to-date, compared to $21.3 million in 2020. This slight increase was the result of costs to complete Arc development and Pheno II program investment.
- Net loss was $77.7 million, or $1.26 per share, which included $22.0 million in non-cash stock-based compensation expense and a $4.5 million non-cash inventory write-down. Net loss excluding non-cash charges was $51.2 million, or $0.83 per share.
- Net cash used was $47.2 million, and the company ended the year with total cash, investments, and cash equivalents of $63.6 million.
Full financial results for the year ending December 31, 2021, will be filed on Form 10-K through the Securities and Exchange Commission’s (SEC) website at http://www.sec.gov.
Audio Webcast and Conference Call
The company will host a conference call at 4:30PM ET today to review its fourth quarter and full year 2021 results. To listen to the 2021 fourth quarter and full year 2021 financial results call by phone, +1.877.883.0383 and enter Elite Entry Number: 8732862. International participants may dial +1.412.902.6506. Please dial in 10–15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 7365004 until March 29, 2022.
This conference call will also be webcast and can be accessed from the “Investors” section of the company’s website at ir.axdx.com. A replay of the audio webcast will be available until June 8, 2022.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and “ACCELERATE ARC” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as, among others, Mr. Phillips statements regarding strong research and development initiatives enabling sales of new products, customer interest in PhenoAST and Accelerate Arc leading to future sales, the expected launch of the Accelerate Arc instrument in March 2022, and our expectation for improved commercial activity because of strong interest in our new products and an improved hospital environment in 2022. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 2, 2021, and in any other reports that the company files with the Securities and Exchange Commission. The company’s forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
| ACCELERATE DIAGNOSTICS, INC. | ||
| CONSOLIDATED | ||
| BALANCE SHEETS | ||
| (in thousands, except share data) | ||
| December 31, | ||
| 2021 | 2020 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $39,898 | $35,781 |
| Investments | 23,720 | 32,488 |
| Trade accounts receivable | 2,320 | 1,550 |
| Inventory | 5,067 | 9,216 |
| Prepaid expenses | 768 | 1,172 |
| Other current assets | 1,558 | 1,780 |
| Total current assets | 73,331 | 81,987 |
| Property and equipment, net | 5,389 | 6,135 |
| Right of use assets | 2,510 | 3,183 |
| Other non-current assets | 1,817 | 2,120 |
| Total assets | $83,047 | $93,425 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $1,983 | $1,290 |
| Accrued liabilities | 2,853 | 2,991 |
| Accrued interest | 909 | 1,262 |
| Deferred revenue | 451 | 376 |
| Current portion of long-term debt | 80 | 553 |
| Current operating lease liability | 669 | 497 |
| Total current liabilities | 6,945 | 6,969 |
| Non-current operating lease liability | 2,381 | 3,063 |
| Other non-current liabilities | 808 | 335 |
| Long-term debt | — | 4,659 |
| Convertible notes | 107,984 | 141,211 |
| Total liabilities | 118,118 | 156,237 |
| Commitments and contingencies | ||
| Stockholders’ deficit: | ||
| Preferred shares, $0.001 par value; | ||
| 5,000,000 preferred shares authorized and 3,954,546 outstanding as of December 31, 2021 and 5,000,000 preferred shares authorized and none outstanding as of December 31, 2020 | 4 | — |
| Common stock, $0.001 par value; | ||
| 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021 and 85,000,000 common shares authorized with 57,607,939 shares issued and outstanding on December 31, 2020 | 68 | 58 |
| Contributed capital | 580,652 | 475,072 |
| Treasury stock | (45,067) | (45,067) |
| Accumulated deficit | (570,668) | (492,966) |
| Accumulated other comprehensive loss | (60) | 91 |
| Total stockholders’ deficit | (35,071) | (62,812) |
| Total liabilities and stockholders’ deficit | $83,047 | $93,425 |
| ACCELERATE DIAGNOSTICS, INC. | |||
| CONSOLIDATED | |||
| STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||
| (in thousands, except per share data) | |||
| Years Ended December 31, | |||
| 2021 | 2020 | 2019 | |
| Net sales | $11,782 | $11,165 | $9,297 |
| Cost of sales: | |||
| Cost of sales of products and services | 7,663 | 6,706 | 4,897 |
| Inventory write-down | 4,500 | — | — |
| Total cost of sales | 12,163 | 6,706 | 4,897 |
| Gross profit | (381) | 4,459 | 4,400 |
| Costs and expenses: | |||
| Research and development | 21,943 | 21,255 | 25,345 |
| Sales, general and administrative | 49,236 | 46,904 | 51,886 |
| Total costs and expenses | 71,179 | 68,159 | 77,231 |
| Loss from operations | (71,560) | (63,700) | (72,831) |
| Other income (expense): | |||
| Interest expense | (15,545) | (15,550) | (14,256) |
| Gain on extinguishment of debt | 9,793 | — | — |
| Foreign currency exchange (loss) gain | (413) | 252 | (124) |
| Interest and dividend income | 88 | 855 | 2,809 |
| Other expense, net | (20) | (60) | (14) |
| Total other expense, net | (6,097) | (14,503) | (11,585) |
| Net loss before income taxes | (77,657) | (78,203) | (84,416) |
| (Provision) benefit for income taxes | (45) | (5) | 111 |
| Net loss | $(77,702) | $(78,208) | $(84,305) |
| Basic and diluted net loss per share | $(1.26) | $(1.40) | $(1.55) |
| Weighted average shares outstanding | 61,727 | 56,010 | 54,506 |
| Other comprehensive loss: | |||
| Net loss | $(77,702) | $(78,208) | $(84,305) |
| Net unrealized (loss) gain on investments | (34) | (2) | 193 |
| Foreign currency translation adjustment | (117) | 151 | (102) |
| Comprehensive loss | $(77,853) | $(78,059) | $(84,214) |
| ACCELERATE DIAGNOSTICS, INC. | |||||||||
| CONSOLIDATED | |||||||||
| STATEMENTS OF STOCKHOLDERS’ DEFICIT | |||||||||
| (in thousands) | |||||||||
| Preferred | Preferred | Common | Common | Contributed | Accumulated | Treasury | Accumulated | Total | |
| Balances, January 1, 2019 | — | — | 54,232 | $54 | $432,885 | $(330,348) | $(45,067) | $(149) | $57,375 |
| Net loss | — | — | — | — | — | (84,305) | — | — | (84,305) |
| Issuance of common stock | — | — | 56 | — | 1,000 | — | — | — | 1,000 |
| Exercise of options and restricted stock awards issued | — | — | 396 | 1 | 5,364 | — | — | — | 5,365 |
| Issuance of common stock under employee purchase plan | — | — | 25 | — | 458 | — | — | — | 458 |
| Unrealized gain on investments | — | — | — | — | — | — | — | 193 | 193 |
| Foreign currency translation adjustment | — | — | — | — | — | — | — | (102) | (102) |
| Equity-based compensation | — | — | — | — | 12,637 | — | — | — | 12,637 |
| Balances, December 31, 2019 | — | — | 54,709 | 55 | 452,344 | (414,653) | (45,067) | (58) | (7,379) |
| Net loss | — | — | — | — | — | (78,208) | — | — | (78,208) |
| Exercise of options and restricted stock awards issued | — | — | 2,858 | 3 | 6,059 | — | — | — | 6,062 |
| Issuance of common stock under employee purchase plan | — | — | 41 | — | 359 | — | — | — | 359 |
| Unrealized gain on investments | — | — | — | — | — | — | — | (2) | (2) |
| Foreign currency translation adjustment | — | — | — | — | — | — | — | 151 | 151 |
| Cumulative impact of accounting change | — | — | — | — | — | (105) | — | — | (105) |
| Equity-based compensation | — | — | — | — | 16,310 | — | — | — | 16,310 |
| Balances, December 31, 2020 | — | — | 57,608 | 58 | 475,072 | (492,966) | (45,067) | 91 | (62,812) |
| Net loss | — | — | — | — | — | (77,702) | — | — | (77,702) |
| Issuance of common stock | — | — | 4,937 | 5 | 32,400 | — | — | — | 32,405 |
| Exchange of common stock for preferred | — | — | (2,643) | (3) | (20,297) | — | — | — | (20,300) |
| Issuance of preferred stock | 3,955 | 4 | — | — | 30,446 | — | — | — | 30,450 |
| Exercise of options and restricted stock awards issued | — | — | 1,090 | 1 | 1,619 | — | — | — | 1,620 |
| Issuance of common stock under employee purchase plan | — | — | 54 | — | 326 | — | — | — | 326 |
| Unrealized loss on investments | — | — | — | — | — | — | — | (34) | (34) |
| Foreign currency translation adjustment | — | — | — | — | — | — | — | (117) | (117) |
| Issuance of shares in exchange for Convertible Senior Notes | — | — | 6,603 | 7 | 38,896 | — | — | — | 38,903 |
| Equity-based compensation | — | — | — | — | 22,190 | — | — | — | 22,190 |
| Balances, December 31, 2021 | $3,955 | $4 | $67,649 | $68 | $580,652 | $(570,668) | $(45,067) | $(60) | $(35,071) |
| ACCELERATE DIAGNOSTICS, INC. | |||
| CONSOLIDATED | |||
| STATEMENT OF CASH FLOWS | |||
| (in thousands) | |||
| Years Ended December 31, | |||
| 2021 | 2020 | 2019 | |
| Cash flows from operating activities: | |||
| Net loss | $(77,702) | $(78,208) | $(84,305) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 2,518 | 2,997 | 2,602 |
| Amortization of investment discount | 226 | 99 | (427) |
| Equity-based compensation expense | 22,047 | 16,464 | 12,618 |
| Amortization of debt discount and issuance costs | 11,542 | 11,168 | 9,969 |
| Realized loss on available-for-sale securities | — | 3 | — |
| (Gain) loss on disposal of property and equipment | (75) | 785 | 837 |
| Contributions to deferred compensation plan | (484) | (357) | — |
| Gain on extinguishment of debt | (9,793) | — | — |
| Inventory write-down | 4,500 | — | — |
| (Increase) decrease in assets: | |||
| Accounts receivable | (770) | 1,592 | (1,362) |
| Inventory | (415) | (1,356) | (3,655) |
| Prepaid expense and other assets | 1,014 | (2,087) | (752) |
| Increase (decrease) in liabilities: | |||
| Accounts payable | 273 | (1,006) | 988 |
| Accrued liabilities | (469) | (909) | (1,327) |
| Accrued interest | (283) | — | — |
| Deferred revenue and income | 75 | 105 | 54 |
| Deferred compensation | 473 | 316 | (34) |
| Net cash used in operating activities | (47,323) | (50,394) | (64,794) |
| Cash flows from investing activities: | |||
| Purchases of equipment | (603) | (1,362) | (330) |
| Purchase of marketable securities | (30,081) | (46,933) | (50,226) |
| Proceeds from sales of marketable securities | 250 | — | 14,500 |
| Maturities of marketable securities | 38,738 | 61,901 | 88,867 |
| Net cash provided by investing activities | 8,304 | 13,606 | 52,811 |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common and preferred shares | 42,880 | 359 | 1,458 |
| Proceeds from exercise of options | 1,620 | 5,703 | 4,907 |
| Proceeds from issuance of common stocks under employee purchase plan | 326 | 359 | 458 |
| Proceeds from debt | — | 5,578 | — |
| Payment of debt | (360) | (366) | — |
| Common stock issuance cost | (325) | — | — |
| Payment of costs related to debt exchange | (915) | — | — |
| Net cash provided by financing activities | 43,226 | 11,633 | 6,823 |
| Effect of exchange rate on cash | (90) | (78) | (86) |
| Increase (decrease) in cash and cash equivalents | 4,117 | (25,233) | (5,246) |
| Cash and cash equivalents, beginning of period | 35,781 | 61,014 | 66,260 |
| Cash and cash equivalents, end of period | $39,898 | $35,781 | $61,014 |
| ACCELERATE DIAGNOSTICS, INC. | |||||
| CONSOLIDATED | |||||
| STATEMENT OF CASH FLOWS (CONTINUED) | |||||
| (in thousands) | |||||
| Years Ended December 31, | |||||
| 2021 | 2020 | 2019 | |||
| Non-cash investing activities: | |||||
| Net transfer of instruments from inventory to property and equipment | $688 | $1,525 | $3,361 | ||
| Supplemental cash flow information: | |||||
| Interest paid | $4,288 | $4,288 | $4,288 | ||
| Income taxes paid, net of refunds | $— | $43 | $41 | ||
| Extinguishment of Convertible Senior Notes through issuance of common stock | $38,902 | $— | $— | ||
| See accompanying notes to consolidated financial statements. | |||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-reports-fourth-quarter-and-full-year-2021-financial-results-301498359.html
SOURCE Accelerate Diagnostics, Inc.
Company Codes: NASDAQ-SMALL:AXDX
